Contribute Try STAT+ Today

SAN FRANCISCO — Syapse, among the highest profile companies in a wave of startups seeking to mine patient data stored in electronic medical records and other portals, last week laid off 18 of its San Francisco-based employees — a move the company attributes to a shift in focus toward data analytics and insights and away from its software business.

The layoffs — which primarily affected Syapse’s engineering division, along with its product management and operations teams — represented about 10% of its workforce. The realignment comes just weeks after the pharma giant Roche prematurely terminated a precision medicine deal with Syapse centered around oncology data.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I wonder much different this collaboration was versus what Roche already was doing with Flatiron (which they acquired). There seems to be a number of other startups like Picnic Health and Datavant trying to work with life science companies on RWD. I am interested to see what comes out of these collaborations.

Comments are closed.